↓ Skip to main content

American Association for Cancer Research

Article Metrics

Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

Overview of attention for article published in Molecular Cancer Research, June 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter
1 tweeter
patent
10 patents
facebook
1 Facebook page

Citations

dimensions_citation
509 Dimensions

Readers on

mendeley
334 Mendeley
connotea
1 Connotea
Title
Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers
Published in
Molecular Cancer Research, June 2011
DOI 10.1158/1541-7786.mcr-10-0490
Pubmed ID
Authors

Andrew J. Armstrong, Matthew S. Marengo, Sebastian Oltean, Gabor Kemeny, Rhonda L. Bitting, James D. Turnbull, Christina I. Herold, Paul K. Marcom, Daniel J. George, Mariano A. Garcia-Blanco

Abstract

During cancer progression, malignant cells undergo epithelial-mesenchymal transitions (EMT) and mesenchymal-epithelial transitions (MET) as part of a broad invasion and metastasis program. We previously observed MET events among lung metastases in a preclinical model of prostate adenocarcinoma that suggested a relationship between epithelial plasticity and metastatic spread. We thus sought to translate these findings into clinical evidence by examining the existence of EMT in circulating tumor cells (CTC) from patients with progressive metastatic solid tumors, with a focus on men with castration-resistant prostate cancer (CRPC) and women with metastatic breast cancer. We showed that the majority (> 80%) of these CTCs in patients with metastatic CRPC coexpress epithelial proteins such as epithelial cell adhesion molecule (EpCAM), cytokeratins (CK), and E-cadherin, with mesenchymal proteins including vimentin, N-cadherin and O-cadherin, and the stem cell marker CD133. Equally, we found that more than 75% of CTCs from women with metastatic breast cancer coexpress CK, vimentin, and N-cadherin. The existence and high frequency of these CTCs coexpressing epithelial, mesenchymal, and stem cell markers in patients with progressive metastases has important implications for the application and interpretation of approved methods to detect CTCs.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 334 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 3 <1%
Netherlands 2 <1%
United States 2 <1%
Spain 2 <1%
United Kingdom 1 <1%
Saudi Arabia 1 <1%
China 1 <1%
Italy 1 <1%
Germany 1 <1%
Other 0 0%
Unknown 320 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 96 29%
Researcher 65 19%
Student > Master 28 8%
Student > Bachelor 24 7%
Student > Doctoral Student 22 7%
Other 59 18%
Unknown 40 12%
Readers by discipline Count As %
Agricultural and Biological Sciences 82 25%
Biochemistry, Genetics and Molecular Biology 78 23%
Medicine and Dentistry 57 17%
Engineering 32 10%
Chemistry 12 4%
Other 22 7%
Unknown 51 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 November 2021.
All research outputs
#2,606,212
of 19,852,973 outputs
Outputs from Molecular Cancer Research
#145
of 1,687 outputs
Outputs of similar age
#17,351
of 138,896 outputs
Outputs of similar age from Molecular Cancer Research
#4
of 17 outputs
Altmetric has tracked 19,852,973 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,687 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 138,896 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.